RNA Vaccine Regulatory Workshop
On 28 and 29 July 2026, 17 national regulatory authorities from across Latin America and the Carribean came together to work through the regulatory pathways that guide RNA vaccines from the laboratory to public health. The aim was to build reviewer fluency in RNA-vaccine science and to promote regulatory convergence — from the technical basis of the platform through emergency development, reliance, and RNA-specific GMP inspection. Full Report ENGLISH Full Report SPANISH Day 1 SlidesDay 2 Slides |
Responsive Table
| VMFN Partner | WHO LMIC Region | Modality Status at each VMFN Partner | ||
| mRNA | rProtein | Viral Vector | ||
| Aspen (drug product f/f only) | Africa | |||
| IPD | ||||
| Serum Institute of India | SE Asia | |||
| BioFarma | ||||
| Fiocruz-BioManguinhos | LAC | |||
| Samsung Biologics | W Pacific | |||
Key
| Developed | Developing | To be developed |
